CIK 0001781983 · Non-accelerated filer<br>Smaller reporting company
Aprea Therapeutics, Inc.
Sign in to watch- Ticker
- APRE
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 215-948-4119
- Business address
- 3805 OLD EASTON ROAD, DOYLESTOWN, PA, 18902
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 52 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-06-05 | HENNEMAN JOHN B III Director | Grant or award | +1,045 | 10,229 | ||
| 2025-06-05 | HENNEMAN JOHN B III Director | Grant or award · Stock Options (Right to Buy) | +4,185 | 4,185 | ||
| 2025-06-05 | Gruia Gabriela Director | Grant or award | +1,045 | 1,045 | ||
| 2025-06-05 | Gruia Gabriela Director | Grant or award · Stock Options (Right to Buy) | +4,185 | 4,185 | ||
| 2025-06-05 | Grissinger Michael Director | Grant or award | +1,045 | 2,889 | ||
| 2025-06-05 | Grissinger Michael Director | Grant or award · Stock Options (Right to Buy) | +4,185 | 4,185 | ||
| 2025-06-05 | Duey Marc Director | Grant or award | +1,045 | 234,696 | ||
| 2025-06-05 | Duey Marc Director | Grant or award · Stock Options (Right to Buy) | +4,185 | 4,185 | ||
| 2025-06-05 | BIZZARI JEAN-PIERRE Director | Grant or award | +1,045 | 1,045 | ||
| 2025-06-05 | BIZZARI JEAN-PIERRE Director | Grant or award · Stock Options (Right to Buy) | +4,185 | 4,185 | ||
| 2025-04-03 | Gilad Oren President/CEO | Purchase | +3,003 | $1.87 | $6K | 343,123 |
| 2025-04-03 | Gilad Oren President/CEO | Purchase | +2,497 | $1.80 | $4K | 345,620 |
| 2025-03-27 | Hamill John P. SrVP/CFO/Prin Fin & Acct Ofcr | Grant or award | +3,365 | 22,733 | ||
| 2025-03-27 | Hamill John P. SrVP/CFO/Prin Fin & Acct Ofcr | Grant or award · Stock Options (Right to Buy) | +13,460 | 13,460 | ||
| 2025-03-27 | Gilad Oren President/CEO | Grant or award | +6,725 | 340,120 | ||
| 2025-03-27 | Gilad Oren President/CEO | Grant or award · Stock Options (Right to Buy) | +26,900 | 26,900 | ||
| 2024-10-23 | Gilad Oren President/CEO | Purchase | +500 | $3.92 | $2K | 333,395 |
| 2024-10-18 | Duey Marc Director | Sale | −6,462 | $4.58 | $30K | 233,651 |
| 2024-10-16 | Duey Marc Director | Purchase | +30,000 | $4.39 | $132K | 240,113 |
| 2024-10-15 | Gilad Oren President/CEO | Purchase | +250 | $2.90 | $725 | 332,895 |
Page 3 of 10 · 197 trades